These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 3277918)

  • 21. Immunogenicity of an alum-adsorbed synthetic multiple-antigen peptide based on B- and T-cell epitopes of the Plasmodium falciparum CS protein: possible vaccine application.
    de Oliveira GA; Clavijo P; Nussenzweig RS; Nardin EH
    Vaccine; 1994 Aug; 12(11):1012-7. PubMed ID: 7526570
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety, immunogenicity, and pilot efficacy of Plasmodium falciparum sporozoite and asexual blood-stage combination vaccine in Swiss adults.
    Sturchler D; Berger R; Rudin C; Just M; Saul A; Rzepczyk C; Brown G; Anders R; Coppel R; Woodrow G
    Am J Trop Med Hyg; 1995 Oct; 53(4):423-31. PubMed ID: 7485698
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Plasmodium falciparum: elicitation by peptides and recombinant circumsporozoite proteins of circulating mouse antibodies inhibiting sporozoite invasion of hepatoma cells.
    Hollingdale MR; Ballou WR; Aley SB; Young JF; Pancake S; Miller LH; Hockmeyer WT
    Exp Parasitol; 1987 Jun; 63(3):345-51. PubMed ID: 2438152
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Influence of immunoadjuvants and a promiscous T-cell determinant on the immunogenicity of RESA peptide antigen of P. falciparum.
    Chaba B; Kumar P; Haq W; Sabhnani L; Rao DN
    Int J Immunopharmacol; 1998 Jun; 20(6):259-73. PubMed ID: 9754674
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Failure of recombinant vaccinia viruses expressing Plasmodium falciparum antigens to protect Saimiri monkeys against malaria.
    Pye D; Edwards SJ; Anders RF; O'Brien CM; Franchina P; Corcoran LN; Monger C; Peterson MG; Vandenberg KL; Smythe JA
    Infect Immun; 1991 Jul; 59(7):2403-11. PubMed ID: 1711015
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Plasmodium falciparum: administration of anti-sporozoite antibodies during sporogony results in production of sporozoites which are not neutralized by human anti-circumsporozoite protein vaccine sera.
    do Rosario VE; Appiah A; Vaughan JA; Hollingdale MR
    Trans R Soc Trop Med Hyg; 1989; 83(3):305-7. PubMed ID: 2694460
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preclinical evaluation of a synthetic Plasmodium falciparum MAP malaria vaccine in Aotus monkeys and mice.
    Moreno CA; Rodriguez R; Oliveira GA; Ferreira V; Nussenzweig RS; Moya Castro ZR; Calvo-Calle JM; Nardin E
    Vaccine; 1999 Aug; 18(1-2):89-99. PubMed ID: 10501239
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Selection of an adjuvant for vaccination with the malaria antigen, MSA-2.
    Pye D; Vandenberg KL; Dyer SL; Irving DO; Goss NH; Woodrow GC; Saul A; Alving CR; Richards RL; Ballou WR; Wu MJ; Skoff K; Anders RF
    Vaccine; 1997 Jun; 15(9):1017-23. PubMed ID: 9261951
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lipopolysaccharide, lipid A, and liposomes containing lipid A as immunologic adjuvants.
    Alving CR
    Immunobiology; 1993 Apr; 187(3-5):430-46. PubMed ID: 8330907
    [TBL] [Abstract][Full Text] [Related]  

  • 30. IgG2 antibodies against a clinical grade Plasmodium falciparum CSP vaccine antigen associate with protection against transgenic sporozoite challenge in mice.
    Schwenk R; DeBot M; Porter M; Nikki J; Rein L; Spaccapelo R; Crisanti A; Wightman PD; Ockenhouse CF; Dutta S
    PLoS One; 2014; 9(10):e111020. PubMed ID: 25343487
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and immunogenicity of a Plasmodium falciparum sporozoite vaccine: boosting of antibody response in a population with prior natural exposure to malaria.
    Sherwood JA; Oster CN; Adoyo-Adoyo M; Beier JC; Gachihi GS; Nyakundi PM; Ballou WR; Brandling-Bennett AD; Schwartz IK; Were JB
    Trans R Soc Trop Med Hyg; 1991; 85(3):336-40. PubMed ID: 1949134
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of antibody avidity and titre elicited by peptide as a protein conjugate or as expressed in vaccinia.
    Lew AM; Anders RF; Edwards SJ; Langford CJ
    Immunology; 1988 Oct; 65(2):311-4. PubMed ID: 3056855
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Plasmodium falciparum: sporozoite boosting of immunity due to a T-cell epitope on a sporozoite vaccine.
    Hoffman SL; Cannon LT; Berzofsky JA; Majarian WR; Young JF; Maloy WL; Hockmeyer WT
    Exp Parasitol; 1987 Aug; 64(1):64-70. PubMed ID: 2440712
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunogenicity in rabbits and monkeys of influenza ISCOMs conjugated with repeated sequences of the Plasmodium falciparum antigen Pf155/RESA.
    Sjölander A; Hansson M; Lövgren K; Wåhlin B; Berzins K; Perlmann P
    Parasite Immunol; 1993 Jun; 15(6):355-9. PubMed ID: 8361778
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Induction of protective antibodies in Saimiri monkeys by immunization with a multiple antigen construct (MAC) containing the Plasmodium vivax circumsporozoite protein repeat region and a universal T helper epitope of tetanus toxin.
    Yang C; Collins WE; Xiao L; Saekhou AM; Reed RC; Nelson CO; Hunter RL; Jue DL; Fang S; Wohlhueter RM; Udhayakumar V; Lal AA
    Vaccine; 1997 Mar; 15(4):377-86. PubMed ID: 9141208
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Elastic liposome-mediated transdermal immunization enhanced the immunogenicity of P. falciparum surface antigen, MSP-119.
    Tyagi RK; Garg NK; Jadon R; Sahu T; Katare OP; Dalai SK; Awasthi A; Marepally SK
    Vaccine; 2015 Aug; 33(36):4630-8. PubMed ID: 26141014
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lymphocyte responsiveness to a candidate malaria sporozoite vaccine (R32tet32) of individuals with naturally acquired Plasmodium falciparum malaria.
    Webster HK; Ho M; Looareesuwan S; Pavanand K; Wattanagoon Y; Warrell DA; Hockmeyer WT
    Am J Trop Med Hyg; 1988 Jan; 38(1):37-41. PubMed ID: 3277463
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Improved immunogenicity and efficacy of the recombinant 19-kilodalton merozoite surface protein 1 by the addition of oligodeoxynucleotide and aluminum hydroxide gel in a murine malaria vaccine model.
    Near KA; Stowers AW; Jankovic D; Kaslow DC
    Infect Immun; 2002 Feb; 70(2):692-701. PubMed ID: 11796601
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunogenicity of a non-repetitive sequence of Plasmodium falciparum circumsporozoite protein in man and mice.
    Del Giudice G; Cheng Q; Mazier D; Berbiguier N; Cooper JA; Engers HD; Chizzolini C; Verdini AS; Bonelli F; Pessi A
    Immunology; 1988 Feb; 63(2):187-91. PubMed ID: 2450833
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunization trials with the ring-infected erythrocyte surface antigen of Plasmodium falciparum in owl monkeys (Aotus vociferans).
    Collins WE; Pappaioanou M; Anders RF; Campbell GH; Brown GV; Kemp DJ; Broderson JR; Coppel RL; Skinner JC; Procell PM
    Am J Trop Med Hyg; 1988 Mar; 38(2):268-82. PubMed ID: 3281493
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.